MAIA Biotechnology, Inc. Stock up 8.78% since IPO

MAIA Biotechnology, Inc. MAIA has opened its shares for public trading for the first time since filing for an IPO in April 2022. The company has agreed to initially offer 2, 00 million shares to the public at a $5.00 per share. On its first day of trading, the stock rose 8.78% from its opening price of $4.1 to its closing price of $4.46.

Performance of MAIA Biotechnology, Inc. on the first day of trading About MAIA Biotechnology, Inc. and its IPO

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies against cancer. THIO, our lead asset, is an investigational drug candidate with a dual mechanism of action integrating telomere targeting and immunogenicity.

For its IPO, MAIA has agreed to offer 2.00 million shares at a price of $5.00 per share, with an insider lock-in period of 180 days, ending January 24, 2023.

An insider lock-in period is a period after a company's initial public offering during which major shareholders are not permitted to sell their shares. The insider lock-in period ensures that the market is not oversupplied with company stock.

Traders can short the stock until the expiry date of the core-block period in the hope that the price will fall due to an increase in supply of shares. Retail traders should watch for short interest in this security as it nears lockout expiration.

See also: Benzinga's Best Selling Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.